Next Science Limited Investor Presentation 28 February 2020 - PowerPoint PPT Presentation

Innovations powered by technology Next Science Limited Investor Presentation 28 February 2020 Approved by the Board of Next Science Limited 1

Disclaimers (HWL) This presentation has been prepared by Next Science Limited ACN 622 382 549 ( Next Science ), based on information available as at the date of this presentation, and is provided for general information purposes only. No party other than Next Science has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation. This presentation is provided in summary form and is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. To the maximum extent permitted by law, Next Science and each of its shareholders, directors, officers, agents, employees or advisers, and any of their respective affiliates or related bodies corporate, make no warranty or representation (express or implied) as to the accuracy, reliability, timeliness or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward looking statements) expressed in this presentation are subject to change without notice. This presentation is not a prospectus, product disclosure statement, pathfinder document or any other type of public offer disclosure document for the purposes of the Corporations Act 2001 (Cth) ( Corporations Act ) and has not been, and is not required to be, lodged with the Australian Securities and Investments Commission. This presentation is not intended to constitute legal, tax, accounting or other advice and does not take into account any individual’s investment objectives, taxation situation, financial situation or needs, nor is it a recommendation to acquire any entitlements or securities in Next Science. This presentation may include forward-looking statements, including statements about Next Science's financial results, guidance and/or business prospects that may involve risks or uncertainties and may involve significant items of subjective judgement and assumptions of future events that may or may not eventuate. Forward looking statements can generally be identified by the use of forward looking words such as “anticipate”, “likely”, “expect”, “intend”, “should”, “could”, “may”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Next Science or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved. Investors should form their own views as to these matters and any assumptions on which any of the forward looking statements are based and not place reliance on such statements. An investment in the securities in Next Science is subject to known and unknown risks, many of which are beyond the control of Next Science, including factors and risks specific to the industry in which Next Science operates as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets. Next Science does not guarantee any particular rate of return or the performance of Next Science, nor does it guarantee any particular tax treatment. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Next Science is not licensed to provide financial product advice in respect of Next Science securities or any other financial products. Any references to or explanations of legislation, regulatory issues, benefits or any other legal commentary (if any) are indicative only, do not summarise all relevant issues and are not intended to be a full explanation of a particular matter. To the maximum extent permitted by law, neither Next Science, nor any of its officers, directors, employees, agents and advisers, nor any other person, accepts any responsibility or liability for the content, accuracy or completeness of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. In particular, but without prejudice to the generality of the foregoing, no representation, warranty or assurance is given as to the achievement or reasonableness of any future projections, management projections, management estimates or prospects contained in this presentation. This disclaimer also extends to all and any information and opinions contained in, and any omissions from, any other written or oral communications transmitted or otherwise made available to the recipient in connection with this presentation. The distribution of this presentation to persons or in jurisdictions outside Australia may be restricted by law and any person into whose possession this document comes should seek advice on and observe those restrictions. Any failure to comply with such restrictions may violate applicable securities law. To the maximum extent permitted by law, Next Science and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation). Investor Presentation – February 2020 2

CEO messages “ Our purpose at Next Science is to heal patients and save lives by addressing the impacts of biofilms on human health, and to commercialise our Xbio technology platform for shareholders. We have a unique opportunity to change the trajectory of the war on infection by providing solutions that eliminate biofilms. 2019 was a year of achievements and learnings – we listed on the ASX in April raising A$35m to fund our product development and growth and we launched two new products to market. We also learnt many lessons about bringing disruptive technologies to market including partnership management, proving our product value and continuing to develop clinical support with key opinion leaders. We enter 2020 with momentum. Our focus is to continue to grow our revenue through a range of commercial efforts with several distribution and partnership models. We will launch 5 new products through the year while continuing to expand our patent and regulatory approval portfolios and build further clinical support for our products.” Investor Presentation – February 2020 3

The Science “80% of infections in humans are in a biofilm” (CDC 2011) The Solution – Xbio TM Technology Deconstruct the bacterial biofilm barrier Xbio TM is the only non-toxic Next Science's Xbio technology breaks the ionic bonds that hold the biofilm together. The polymers are then pulled into solution, effectively dissolving the biofilm barrier. solution to deconstruct the bacteria’s protective barrier. We’ve applied material science Destroy the bacteria within, through cell lysis 1 innovation to physically With the barrier dissolved, bacteria are exposed and more vulnerable to attack. Bacteria enveloped deconstruct the bacteria’s by Xbio technology experience cell lysis and are destroyed. protective structures, exposing Cell lysis is non-discriminatory destroying gram-positive and gram-negative bacteria, persister cells, and spores. There is no known resistance mechanism to cell lysis . and then eradicating bacteria through cell lysis 1 , rather than using toxic or resistance Defend from recolonisation building ingredients . The periodic release of bacteria from biofilms has been linked to chronic relapsing infections. 2 Disrupting and destroying the biofilm barrier can reduce the rate of biofilm recurrence by up to 1,000 times, effectively defending against recolonization. 3 Unlike other agents that claim to destroy biofilms, there is no known evidence of bacterial resistance to the Xbio technology. 1. Lysis: disintegration by rupturing the cell membrane. 2. Costerton JW et al. Investor Presentation – February 2020 4 3. Potera C:antibiotic resistance: biofilm dispersing agent rejuvenates older antibiotics” Environmental Health Perspectives 118 (7) 228 .